CN1378534A - 用于选择性抑制凝血级联的取代的多环芳基和杂芳基吡啶酮类化合物 - Google Patents

用于选择性抑制凝血级联的取代的多环芳基和杂芳基吡啶酮类化合物 Download PDF

Info

Publication number
CN1378534A
CN1378534A CN00810182A CN00810182A CN1378534A CN 1378534 A CN1378534 A CN 1378534A CN 00810182 A CN00810182 A CN 00810182A CN 00810182 A CN00810182 A CN 00810182A CN 1378534 A CN1378534 A CN 1378534A
Authority
CN
China
Prior art keywords
group
amino
hydrogen
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00810182A
Other languages
English (en)
Chinese (zh)
Inventor
M·索斯
Q·曾
M·L·鲁佩尔
J·J·帕罗
A·T·哈姆泄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of CN1378534A publication Critical patent/CN1378534A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN00810182A 1999-05-19 2000-05-15 用于选择性抑制凝血级联的取代的多环芳基和杂芳基吡啶酮类化合物 Pending CN1378534A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13481199P 1999-05-19 1999-05-19
US60/134,811 1999-05-19

Publications (1)

Publication Number Publication Date
CN1378534A true CN1378534A (zh) 2002-11-06

Family

ID=22465131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00810182A Pending CN1378534A (zh) 1999-05-19 2000-05-15 用于选择性抑制凝血级联的取代的多环芳基和杂芳基吡啶酮类化合物

Country Status (21)

Country Link
EP (1) EP1178964A1 (xx)
JP (1) JP2002544260A (xx)
KR (1) KR20010113970A (xx)
CN (1) CN1378534A (xx)
AR (1) AR029635A1 (xx)
AU (1) AU771928B2 (xx)
BR (1) BR0011272A (xx)
CA (1) CA2373509A1 (xx)
CZ (1) CZ20014117A3 (xx)
EA (1) EA005367B1 (xx)
HU (1) HUP0201996A3 (xx)
IL (1) IL146244A0 (xx)
MX (1) MXPA01011805A (xx)
MY (1) MY138303A (xx)
NO (1) NO20015606L (xx)
NZ (1) NZ514875A (xx)
PL (1) PL352403A1 (xx)
SK (1) SK15862001A3 (xx)
UY (1) UY26154A1 (xx)
WO (1) WO2000069826A1 (xx)
ZA (2) ZA200109340B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164122A (zh) * 2013-03-28 2015-12-16 拜耳制药股份公司 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
CA2405306A1 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
WO2001077097A2 (en) 2000-04-05 2001-10-18 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
WO2001079195A2 (en) * 2000-04-14 2001-10-25 Corvas International, Inc. Pyridine and pyrazine derivatives as thrombin inhibitors
CA2405684A1 (en) 2000-04-17 2001-10-25 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
AU2001217827A1 (en) * 2000-05-18 2001-11-26 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
CA2433158C (en) 2000-12-28 2011-05-10 Shionogi & Co., Ltd. Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor
WO2003093242A2 (en) 2001-10-03 2003-11-13 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2003048127A1 (en) * 2001-12-04 2003-06-12 Corvas International, Inc. Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508558A (ja) * 1995-06-27 1999-07-27 メルク エンド カンパニー インコーポレーテッド ピリジノン トロンビン阻害剤
CA2245811A1 (en) * 1996-02-22 1997-08-28 Merck & Co., Inc. Pyridinone thrombin inhibitors
WO1999011267A1 (en) * 1997-09-05 1999-03-11 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP0932608A1 (en) * 1996-10-11 1999-08-04 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US5792779A (en) * 1997-02-19 1998-08-11 Merck & Co., Inc. Pyridinone thrombin inhibitors
EP0969840A4 (en) * 1997-03-24 2001-02-28 Merck & Co Inc THROMBIN INHIBITORS
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
ATE306261T1 (de) * 1997-06-26 2005-10-15 Lilly Co Eli Antithrombosemittel
ATE344246T1 (de) * 1997-11-26 2006-11-15 Ortho Mcneil Pharm Inc Heteroaryl aminoguanidin- und alkoxyguanidinderivate und ihre verwendung als proteasehemmer
JP2002525370A (ja) * 1998-09-28 2002-08-13 メルク エンド カムパニー インコーポレーテッド トロンビン阻害剤
CA2348530A1 (en) * 1998-10-30 2000-05-11 Merck & Co., Inc. Thrombin inhibitors
AU747776B2 (en) * 1998-10-30 2002-05-23 Merck & Co., Inc. Thrombin inhibitors
FR2786482B1 (fr) * 1998-11-27 2002-08-09 Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164122A (zh) * 2013-03-28 2015-12-16 拜耳制药股份公司 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途
CN105164122B (zh) * 2013-03-28 2018-02-02 拜耳制药股份公司 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途
CN108164513A (zh) * 2013-03-28 2018-06-15 拜耳制药股份公司 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途
CN108164513B (zh) * 2013-03-28 2021-05-07 拜耳制药股份公司 取代的氧代吡啶衍生物及其在治疗心血管病症方面的用途

Also Published As

Publication number Publication date
MXPA01011805A (es) 2003-09-04
BR0011272A (pt) 2002-05-07
KR20010113970A (ko) 2001-12-28
WO2000069826A1 (en) 2000-11-23
AU4797300A (en) 2000-12-05
IL146244A0 (en) 2002-07-25
MY138303A (en) 2009-05-29
NZ514875A (en) 2004-10-29
HUP0201996A3 (en) 2002-12-28
CA2373509A1 (en) 2000-11-23
ZA200109340B (en) 2004-05-26
NO20015606L (no) 2002-01-21
AR029635A1 (es) 2003-07-10
SK15862001A3 (sk) 2002-08-06
EA005367B1 (ru) 2005-02-24
CZ20014117A3 (cs) 2002-05-15
JP2002544260A (ja) 2002-12-24
UY26154A1 (es) 2000-12-29
ZA200400449B (en) 2004-11-24
HUP0201996A2 (en) 2002-09-28
NO20015606D0 (no) 2001-11-16
EP1178964A1 (en) 2002-02-13
EA200101213A1 (ru) 2002-04-25
AU771928B2 (en) 2004-04-08
PL352403A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
CN1378534A (zh) 用于选择性抑制凝血级联的取代的多环芳基和杂芳基吡啶酮类化合物
CN1157380C (zh) 可用作抗凝血剂的取代的多环芳基与杂芳基嘧啶酮
CN1152023C (zh) 作为抗凝血剂的取代的多环芳基与杂芳基尿嘧啶
CN1105114C (zh) 芳族磺酰基α－羟基异羟肟酸化合物
CN1259307C (zh) 酰化的二氢化茚基胺及其作为药物的用途
CN1097051C (zh) N－杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1207289C (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1178917C (zh) 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
CN1688573A (zh) 糖原合成酶激酶3的吡咯基抑制剂
CN1518546A (zh) 作为vegrf-2和vegfr-3抑制剂的选择性邻氨基苯甲酰胺吡啶酰胺
CN1304406A (zh) 作为玻连蛋白拮抗剂的杂环甘氨酰β－丙氨酸衍生物
CN1246857A (zh) 取代的嘧啶酮和吡啶酮化合物和它们的应用
CN1656073A (zh) 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物
CN1230884A (zh) 硫羟砜金属蛋白酶抑制剂
CN1342139A (zh) 丝氨酸蛋白酶抑制剂
CN1639161A (zh) 炔－芳基磷酸二酯酶－4抑制剂
CN1391555A (zh) 苯甲酰胺和相关的因子Xa抑制剂
CN1839126A (zh) 用于治疗癌症和其它病症的新的氰基吡啶衍生物
CN1236358A (zh) 取代的n－[(氨基亚氨基甲基或氨甲基)苯基]丙基酰胺
CN1320118A (zh) 作为蛋白质酪氨酸激酶抑制剂的取代的3－氰基喹啉
CN1282329A (zh) 作为抗凝剂的邻氨基苯甲酰胺衍生物
CN1950372A (zh) 咪唑并吡啶化合物
CN1839133A (zh) 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用
CN1993347A (zh) 钾通道抑制剂
CN1106007A (zh) 新的磺酰氨基嘧啶类化合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Inventor

Correct: M.S. South|A*T*Hamm III

False: M. Soss|A * T * Ham

Number: 45

Page: 183

Volume: 18

CI02 Correction of invention patent application

Correction item: Inventor

Correct: M.S. South|A*T*Hamm III

False: M. Soss|A * T * Ham

Number: 45

Page: The title page

Volume: 18

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: M. SOUTH A T HARM CHINA TO: M.S. SOUTH A T HAMM III

ERR Gazette correction

Free format text: CORRECT: INVENTOR; FROM: M. SOUTH A T HARM CHINA TO: M.S. SOUTH A T HAMM III

AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1050691

Country of ref document: HK